

DIVERSITY IN ANTIOXIDANT RESPONSE ENZYMES IN PROGRESSIVE STAGES OF HUMAN NON-ALCOHOLIC FATTY LIVER DISEASE

Rhiannon N. Hardwick, Craig D. Fisher, Mark J. Canet, April D. Lake, Nathan J. Cherrington

Department of Pharmacology and Toxicology, University of Arizona, Tucson AZ, USA

Supplemental Data Table 1.

Human Oligonucleotide Probe Sets.

Gene	Function	Probe Sequence
NQO1	CE	cagatggccttctttataagccaTTTTTctcttgaaagaaagt
	CE	gcggtccagcttctttgTTTTTctcttgaaagaaagt
	CE	ccagccttcagaatggcagTTTTTctcttgaaagaaagt
	CE	tggagtgtgcccaatgctatatTTTTTctcttgaaagaaagt
	LE	aagttcgcagggtcctcagtTTTTTaggcataggaccctgtct
	LE	gaacagactcggcaggatactgaTTTTTaggcataggaccctgtct
	LE	ttcagccacaatatctgggctTTTTTaggcataggaccctgtct
	LE	ggactccaaaccactgcaggTTTTTaggcataggaccctgtct
	LE	tctcctatgaacactcgctcaaaTTTTTaggcataggaccctgtct
	LE	acattcatgtcccgtggatTTTTTaggcataggaccctgtct
	LE	ttgaattcgggctctgcTTTTTaggcataggaccctgtct
	LE	gttcttccatcctccaggatTTTTTaggcataggaccctgtct
	LE	tcatcccaaataattcaggcTTTTTaggcataggaccctgtct
	BL	gggaactggaatatcacaaggct
	BL	ggcagcgtaagtgaagcaaac
	BL	cggaagggtccttgcatacat
	BL	tgaaagcactgccttcttact

DMD #35006

	BL	ccactgccaccagtgggta
	BL	cccttgagagagtacatggag
	BL	cactctgaattggccagagaatg
	BL	agccacagaaatgcagaatgc
	BL	gtcagttgaggttctaagacttga
GCLC	CE	tctgcagcgagctccgtgTTTTTctcttgaaagaaagt
	CE	agttctccagatgctctcttctaaTTTTTctcttgaaagaaagt
	CE	ttactttcctaaatgctgatccaTTTTTctcttgaaagaaagt
	CE	gcattttcttctgtagaatgtctagttTTTTTctcttgaaagaaagt
	LE	caaccatccaccactgcattgTTTTTaggcataggaccctgtct
	LE	ctgttctgggccttgccaTTTTTaggcataggaccctgtct
	LE	tctatgctcatgagggtgtactccTTTTTaggcataggaccctgtct
	LE	tcctcccattgatgatgggTTTTTaggcataggaccctgtct
	LE	tgggtccacatccacttccatTTTTTaggcataggaccctgtct
	LE	ttagcttaggtagttcagaatactacatcTTTTTaggcataggaccctgtct
	LE	catccatctggcaactgtcattTTTTTaggcataggaccctgtct
	LE	gatggttgcgataaactccctTTTTTaggcataggaccctgtct
	LE	catttgaatttgggtacacttcaTTTTTaggcataggaccctgtct
	LE	agtaactctgggcattcacataatTTTTTaggcataggaccctgtct
	LE	ggatgagtcagtttactccactataTTTTTaggcataggaccctgtct
	LE	ggtagctagccagttcgtcaataatTTTTTaggcataggaccctgtct
	LE	gggctggctgagaggcatTTTTTaggcataggaccctgtct
	BL	ggatcagtcaggaaacacacct
	BL	gtttcaaggtaagagttcagaattg
	BL	tatgacactgtcttgctttagtcag

DMD #35006

	BL	aaataaggctataattcatttcacagt
GCLM	CE	aagagcttcttgaaactgctTTTTTctcttgaaagaaagt
	CE	aaatgtagccttttgattgataattTTTTTctcttgaaagaaagt
	CE	caatttctctcatattgaaggaaattaTTTTTctcttgaaagaaagt
	LE	gaatgtaggaatgctttctgTTTTTtagcataggaccgtgtct
	LE	gcaccactcgtgcgctTTTTTtagcataggaccgtgtct
	LE	accgcagtagccacagcgTTTTTtagcataggaccgtgtct
	LE	cctctactttcacatgaccgaatTTTTTtagcataggaccgtgtct
	LE	caggcagtaactagattttacacatctTTTTTtagcataggaccgtgtct
	LE	atctgcctcaatgacaccatttaTTTTTtagcataggaccgtgtct
	BL	aagaacccttcttttagcttga
	BL	caggtaagttatgctcctaagtcagtt

Supplemental Data Table 2.

Human qPCR Primers.

Gene	Accession Number	Primers	Probe
GST A1	NM 000463.2	Forward: tatctccagcttccctctgc Reverse: gcttcttctaaagatttctcatcca	64
GST A2	NM 000846.3	Forward: ttccagcttccctctgct Reverse: tgattcttctaaagatttctcatcca	64
GST A4	NM 001512.3	Forward: agttgtacaagttgcaggatgg	62

DMD #35006

Reverse: caattcaaccatgggcact

GST M1 NM 000561.2 Forward: gacttcatctcccgcttga 28

Reverse: ccagacagccatctga

GST M2 NM 000848.2 Forward: ggacttcatctcccgattg 28

Reverse: tctttgtgaacacaggtcttg

GST M3 NM 000849.4 Forward: gtgggataaaggcccagact 31

Reverse: gtcttagccttaactggaaatgc

GST M4 NM 000850.3 Forward: acttcatctcccgcttggag 28

Reverse: cccttggtacagaggttttg

GST P1 NM 000852.2 Forward: tcctcatctacaccaactatgag 56

Reverse: ggttcttgctccctggtt